Gleevec All Financial Data in US $ (mln)
Worldwide
 
Overview
 

Word Search (Top 10 - by date)

Novartis Delivered Solid Sales Growth, Margin Expansion and Pipeline Progress in 2014
Novartis (January 27, 2015)
Professor Shiloh, Israel Cancer Research Fund "Research Professor" Awarded First Olav Thon Foundation Prize
Cancer Genetics (January 22, 2015)
Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board
Raze Therapeutics (January 07, 2015)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan (December 10, 2014)
Six-year pivotal study data reinforce the superiority of Tasigna® over Gleevec® in newly-diagnosed patients with Ph+ CML
Molecular Response (December 08, 2014)
Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
Novartis (December 02, 2014)
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Bio-Matrix Scientific Group (December 01, 2014)
Saladax Biomedical Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test
Saladax Biomedical (December 01, 2014)
Project Innovation Launches the Cancer Medicines Interactive Timeline to Highlight the Need for Continued Cancer Innovation in the U.S.
Medical Advances (November 20, 2014)
Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting
Bristol-Myers Squibb (November 07, 2014)

Displaying 10 out of a possible 604 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Gleevec
Generic Name:   imatinib mesylate
Therapeutic Subcategory:     Other cytostatics

Product Sales Summary 2012/13

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2011
Gleevec2 4,659

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Gleevec3 632

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product:4 Gleevec

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now